IDHC Share Price Performance
US$0.63
0.19 (42.94%)
21.1% undervalued intrinsic discount
US$0.80
Fair Value
Price US$0.63
AnalystConsensusTarget US$0.80
AnalystHighTarget US$0.91
AnalystLowTarget US$0.46
Fair ValueUS$0.80
Share Pricen/a
Integrated Diagnostics Holdings plc Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 64 Fair Values set on narratives written by author
IDHC Community Narratives
AN
Fair Value US$0.8 21.1% undervalued intrinsic discount
Acquisition And Branch Expansion Will Unlock Middle East Opportunities
2users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
Fair Value US$0.91 30.5% undervalued intrinsic discount
Digital And House-Call Diagnostics Will Transform MENA Healthcare Delivery
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$0.46 38.5% overvalued intrinsic discount
Egypt, Nigeria Risks Will Curtail Prospects Yet Saudi Will Emerge
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Acquisition And Branch Expansion Will Unlock Middle East Opportunities
Key Takeaways Strategic repricing and acquisition initiatives in Saudi Arabia position IDH for increased revenue growth and margin improvements as operations scale. Expansion of new branches in Egypt and focus on radiology in Saudi Arabia poised to capture market share and boost earnings.Read more
233
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
32users have followed this narrative
AN
US$0.8
21.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
18.98% p.a.
Profit Margin
20.06%
Future PE
11.9x
Price in 2028
US$0.98
Digital And House-Call Diagnostics Will Transform MENA Healthcare Delivery
Key Takeaways Scale improvements and easing macro pressures in key markets are driving stronger-than-expected margin expansion and greater financial flexibility for broader growth. Strategic digital, home-based, and advanced diagnostic service expansion positions the company for accelerated revenue growth and long-term leadership across targeted regions.Read more
40
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$0.91
30.5% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
16.89% p.a.
Profit Margin
19.49%
Future PE
14.72x
Price in 2028
US$1.11
Egypt, Nigeria Risks Will Curtail Prospects Yet Saudi Will Emerge
Key Takeaways Heavy geographic concentration heightens vulnerability to local risks, while slow diversification tempers the benefits of expanding into new markets. Rising digital healthcare adoption and intensifying competition threaten core lab volumes and margin growth, challenging the long-term traditional business model.Read more
22
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$0.46
38.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
24.02% p.a.
Profit Margin
18.98%
Future PE
7.59x
Price in 2028
US$0.56
Trending Discussion
Recently Updated Narratives
AN
IDHC: Steady Margins And Cash Flows Will Support Share Price Upside
Fair Value: US$0.8 21.1% undervalued intrinsic discount
32 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Egypt, Nigeria Risks Will Curtail Prospects Yet Saudi Will Emerge
Fair Value: US$0.46 38.5% overvalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digital And House-Call Diagnostics Will Transform MENA Healthcare Delivery
Fair Value: US$0.91 30.5% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Integrated Diagnostics Holdings plc Key Details
About IDHC
- Founded
- 1979
- Employees
- 6309
- CEO
- WebsiteView website
Integrated Diagnostics Holdings plc operates as a consumer healthcare company that provides medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, such as positron emission tomography - computed tomography (PET-CT), MRI, computed tomography (CT), mammography, ultrasound, X-Ray, electromyography, electroencephalography, electroencephalogram, and electrocardiogram, as well as operates cath lab facilities. It operates in Egypt, Sudan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is based in Saint Helier, Jersey.
